HIF1A and triple-negative breast carcinoma: This work also has potential clinical implications given that it has been proposed that treatment with antiangiogenic agents should be combined with CSC-targeting drugs, since HIF1α increases breast CSCs [27], and that chemotherapy should be combined with HIF inhibitors in women with triple negative breast cancer [28].